top of page



The primary aim of the TTV GUIDE TX consortium is the rapid translation of TTV-guided immunosuppression to standard clinical practice to maximise patient benefit. Full transparency of project activities, particularly with regard to ethical and regulatory issues and visibility of the project and of European-funded research have to be ensured. The website as a main communication channel will include press releases, scientific publications and other information (e.g. meeting reports, videos, social network links, and flyer/poster/folder) in separate sections for the general public and for patients, clinicians and scientists.

cordis logo.PNG

Find results at

The Community Research and Development Information Service


The  TTV GUIDE TX project will participate in the Pilot on Open Research Data in Horizon 2020, which aims to improve and maximise access to and re-use of research data generated by actions. In order to underpin wide dissemination and uptake of the knowledge and results generated in TTV GUIDE TX project among the scientific community, the consortium is committed to publishing all results open access.

Scientific publications


TTV for monitoring of Belatacept based immunosuppression

Project partners in Grenoble suggest that TTV range defined for calcineurn inhibitor based immunosuppression, might also be applicable for kidney transplant recipients with Belatacept based immunosuppression. Project partners from Vienna wrote the acompaning editorial.


Torque Teno Virus for Assessment of
Immunosuppressive Burden in ABOi and HLAi Kidney Transplantation.

A manuscript by project partner in Vienna suggest that high immunosuppressive burden, assessed by TTV, rather than an “intrinsic attribute”, may contribute to higher rates of Polyoma virus nephropathy in ABOi kidney transplant recipients.


TTV in CMV and BKV infection in pediatric KTX

Partners in Vienna demonstrated an association between Torque Teno viral load and CMV and BKV infection in pediatric and adolescent kidney transplant patients.


Review on TTV in Hematological Patients

Project partners in Spain have summarized the evidence of Torque Teno Virus as an Immune Status Biomarker in Adult Hematological Patients.


TTV species diversity and variability

Projekt partners at bioMérieux have analyzed Torque Teno virus diversity and variability in renal transplant recipients.


TTV kinetic following calcineurin inhibitor dose change

Projekt partners from the Medical University of Vienna analysed the kinetics of TTV plasma load following calcineurin inhibitor (CNI) dose change in kidney transplant recipients: TTV load changes become noticeable only 2 months after CNI dose adaptation.

Project partners from the University of Groningen have associated TTV load with smoking, alcohol consumption and HDL.


Editorial on TTV dynamic following adaptations in immunosuppression.

Project partners a the Medical University Vienna reviewed the work of colleagues from Heidelberg (Germany) on TTV dynamic following changes in mycophenolic acid in kidney transplant patients.

Screenshot 2023-07-16 213933.png

TTV for prediction of immune response to COVID-19 vaccination

Project partners in France, Austria and Germany have demonstrated the value of TTV Plasma load for the prediction of humoral and cellular immune response to COVID-19 mRNA .


Review on TTV and other Anelloviruses

Project Partners in Italy on classification, structure, genome, life cycle, epidemiology and clinical features,  of TTV and other Anelloviruses.


Review on TTV  in solid organ transplantation

TTV plasma load is associated with organ rejection and infection, and cutoff values for risk stratification of such events have been proposed for lung and kidney transplantation.


Validation of CE-certified TTV PCR

Projekt partners from the Medical University of Vienna, bioMerieux an Rome validated plasma Torque Teno viral load quantified by a commercially available CE-certified PCR for risk stratification of rejection and infection post kidney transplantation.


Trial protocol TTVguideIT trial

A multicentre, patient‑ and assessor‑blinded, non‑inferiority, randomised and controlled phase II trial to compare standard and torque teno virus‑guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT

bottom of page